Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase NA 4Phase 3 4Phase 1/2 2Phase EARLY_PHASE1 1Phase 4 1Phase 2/3 1Phase 1 1

Status

Completed 5Recruiting 4Terminated 2Not yet recruiting 2Unknown 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1CNS 1Breast 1

Conditions

Sarcoma, Synovial 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Medulloblastoma 1Leukemia, Myeloid, Acute 1Leiomyosarcoma 1Cognitive Dysfunction 1Breast Neoplasms 1

Interventions

Carboplatin 98Cisplatin 95pembrolizumab 91Gemcitabine 81Paclitaxel 79Docetaxel 70Capecitabine 64Oxaliplatin 53Fluorouracil 51Specimen Handling 50Magnetic Resonance Spectroscopy 49Bevacizumab 49Radiotherapy 48Dexamethasone 45Cyclophosphamide 45Drug Therapy 39Leucovorin 38Doxorubicin 37Pemetrexed 35Irinotecan 34Injections 30Rituximab 29Vincristine 28Trastuzumab 26Radiosurgery 26Prednisone 26Lenalidomide 25Etoposide 25130-nm albumin-bound paclitaxel 25Radiation 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 3 × Recruiting × Tablets × Clear all
NCT05907057 2026-05-08

An Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy.

Servier

Phase 3 Recruiting
245 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT05230758 2026-05-01

Met Med Can

The Hospital for Sick Children

Phase 3 Recruiting
140 enrolled
CNS

Medulloblastoma, Cognitive Dysfunction

NCT03016819 2026-02-25

APROMISS

Advenchen Laboratories, LLC

Phase 3 Recruiting
325 enrolled
Sarcoma

Leiomyosarcoma, Sarcoma, Sarcoma, Synovial, Sarcoma, Alveolar Soft Part

NCT04601116 2021-01-14

The MASTER Study (MAmmary Cancer STatin ER Positive Study)

Aarhus University Hospital

Phase 3 Recruiting
3,360 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡